"The report completely disposes of the drug industry's argument that they need 12 to14 years of exclusive marketing, indeed that they need any additional exclusivity, to sustain innovation.  The FTC has provided an unbiased, expert analysis of all the arguments and has definitively concluded that patents and market-based pricing provide more than enough incentive to invest in important new medicines.  This is good news for consumers, who will have early access to affordable versions of life-saving drugs without compromising future breakthroughs."